CTOs on the Move

Wellbeing Digital Sciences

www.wellbeingdigital.co

 
Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

ELPRO SERVICES

ELPRO SERVICES is a Marietta, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

United Home Health Services

United Home Health Services has been serving the community for 22 years. Five dedicated women professionals, including three nurses, a social worker, and a psychiatrist, established UHHS in 1983. This group of professionals identified the need to make a

BlackSea Technologies

BlackSea Technologies is a naval technology firm that enables new asymmetric strategies so U.S. Naval and military forces can prevail over the next several decades in multi-dimensional conflicts.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.

Ambulnz

were innovating medical transportation & changing the standards of ambulance service to improve the lives of emts, patients & healthcare providers